A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.
Inclusion criteria:
Exclusion criteria:
Capital Federal, C1118AAT, Argentina
Capital Federal, C1185AAT, Argentina
Capital Federal, C1425AWC, Argentina
Capital Federal, C1426ANZ, Argentina
Capital Federal, C1426BOR, Argentina
Capital Federal, C1430ERF, Argentina
Montreal, Migration Data H2L 4M1, Canada
Los Condes, 760-0746, Chile
Saint Pierre - La Réunion, 97448, France
Essen, 45122, Germany
Taipei, 100, Germany
Sant'Andrea Delle Fratte (PG), 06132, Italy
Aichi, Nagoya, 460-0001, Japan
Aichi, Nagoya, 464-8681, Japan
Chiba, Kashiwa, 277-8577, Japan
Fukuoka, Fukuoka, 811-1395, Japan
Hyogo, Kobe, 650-0047, Japan
Ishikawa, Kanazawa, 920-8641, Japan
Kanagawa, Yokohama, 236-0051, Japan
Niigata, Niigata, 951-8566, Japan
Okayama, Kurashiki, 710-8602, Japan
Okayama, Okayama, 700-8558, Japan
Osaka, Osaka-Sayama, 589-8511, Japan
Osaka, Osaka, 534-0021, Japan
Sakai, Osaka, 591-8555, Japan
Palau Pinang, 10990, Malaysia
Wilayah Persekutuan, 5600, Malaysia
Wilayah Persekutuan, 59100, Malaysia
Saint Petersburg, 197758, Russia
Khonkaen, 40002, Thailand